Offspring Biosciences in research collaboration developing alpha-synuclein PET ligand
- Sep 16, 2021
- 1 min read
New publication, “Identification and in vitro characterization of C05-01, a PBB3 derivative with improved affinity for alpha-synuclein” together with Karolinska Institutet, Andrea Varrone research group. The approach used in this study also shows that TMAs are a useful tool for the evaluation of ligands in tissue from different proteinopathies, using both fluorescence and autoradiographic assays
The neuropathological hallmark of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies is the accumulation of α-synuclein. The development of an imaging biomarker for α-synuclein is an unmet need. Investigative compound C05-01 binds to both Lewy bodies and Lewy neurites, and displays specific binding in PD and MSA tissue
Fig. (A) Autoradiography (ARG) showing total and non-specific (NS) binding of [3H]C05-01 (1 nM) in tissue from one PD, one control (CO), and one AD case. The NS binding was determined in the presence of cold C05-01 at 10 µM. (B) ARG showing total [3H]C05-01 binding (1 nM) in a PD sample (amygdala, AMY), in different regions of interest. Co-localization of ARG binding and positive immunoreactivity is shown for α-synuclein (α-syn) and amyloid β (aβ) and negative for tau
